A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...
SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...
GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.
The authors used the U.S. Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated a GLP-1 RA and compared them to patients initiating sulfonylureas, dipeptidyl ...
HealthDay on MSN11d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid CancerGlucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback